Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435670 | 1.00 | HSD17B10 (0.44) | HSD17B10ALOX5APFEN1MEN1TSHR | |
| SCHEMBL30157423 | 0.80 | HTR6 (0.54) | MEN1TSHRKMT2AHTR6TP53 | |
| SCHEMBL11251593 | 0.80 | HTR6 (0.54) | MEN1TSHRKMT2AHTR6TP53 | |
| Hydrochloric Acid SCHEMBL11257797 | 0.78 | HTR6 (0.53) | MEN1TSHRKMT2AHTR6ALDH1A1 | |
| SCHEMBL29066185 | 0.78 | KDM4E (0.40) | HSD17B10ALOX5APFEN1MEN1TSHR | |
| SCHEMBL14659452 | 0.78 | P2RX7 (0.44) | ALOX5APFEN1TSHRHTR6ALDH1A1 | |
| SCHEMBL1267623 | 0.77 | KDM4E (0.46) | MEN1TSHRKMT2ATP53ALDH1A1 | |
| SCHEMBL29435737 | 0.77 | KDM4E (0.46) | MEN1TSHRKMT2ATP53ALDH1A1 | |
| SCHEMBL22858424 | 0.77 | ALOX5AP (0.49) | HSD17B10ALOX5APMEN1TSHRKMT2A | |
| SCHEMBL29508914 | 0.77 | ALOX5AP (0.49) | HSD17B10ALOX5APMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2023-05-11 | — | — | US | disclosed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114072395-A | Heterocyclic compounds and their use for treating helminth infections and diseases | 新基公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020219871-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | HSD17B10 213/4885ALOX5AP 4025/4885FEN1 3032/4885 |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | HSD17B10 1705/4885ALOX5AP 1097/4885FEN1 4783/4885 |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | HSD17B10 1705/4885ALOX5AP 1097/4885FEN1 4783/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | HSD17B10 1705/4885ALOX5AP 1097/4885FEN1 4783/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | HSD17B10 1705/4885ALOX5AP 1097/4885FEN1 4783/4885 |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | HSD17B10 1705/4885ALOX5AP 1097/4885FEN1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.